Management ChangeJul 10, 2026, 04:06 PM
Veraxa Biotech Appoints Carl von Halem as Interim CFO
AI Summary
Veraxa Biotech Holding AG announced the appointment of Carl von Halem as Interim Chief Financial Officer, succeeding Torsten Bürgermeister. Mr. von Halem, who previously served as CFO of Xlife Sciences and was instrumental in VERAXA's IPO, brings extensive experience in corporate finance and the life sciences sector. The company is actively seeking a permanent CFO to support its next phase of expansion and operational growth.
Key Highlights
- Carl von Halem appointed Interim Chief Financial Officer of Veraxa Biotech.
- He succeeds Torsten Bürgermeister, who served for four and a half years.
- Company is in final stages of discussions for a highly qualified permanent CFO.
- Mr. von Halem was CFO of Xlife Sciences, instrumental in VERAXA's public listing.
- He brings extensive experience in corporate finance, life sciences, and MedTech.
- Currently serves as CFO of Xlife Science AG and Managing Director of Xlife Science GmbH.
- Holds a Master's degree in Economics from the Technical University of Berlin.
Price Impact
More from VRXA